Stay updated on Merck & Co. Press Releases

Sign up to get notified when there's something new on the Merck & Co. Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Merck & Co. Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Merck has announced several significant updates, including positive EU CHMP opinion for WELIREG® in treating certain tumors and advanced renal cell carcinoma, as well as promising results from the OlympiA Phase 3 trial for LYNPARZA® in early breast cancer.
    Difference
    78%
    Check dated 2024-12-16T01:36:10.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Merck has made significant advancements, including a 100% complete response rate in a Phase 2 trial for a lymphoma treatment and the initiation of a Phase 3 study for COVID-19 treatment, while also being recognized as one of America's Most Responsible Companies for 2025.
    Difference
    67%
    Check dated 2024-12-08T21:53:17.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    Merck has announced its participation in the Citi 2024 Global Healthcare Conference and reported positive interim results from the pivotal Phase 3 ZENITH trial for WINREVAIR™, while also removing details about its previous participation in the Jefferies London Healthcare Conference and a licensing agreement for LM-299.
    Difference
    59%
    Check dated 2024-11-30T13:54:09.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    Merck has made significant announcements, including the approval of WELIREG® in China for VHL disease, the recommendation to reject TRC Capital’s mini-tender offer, and the election of Surendralal Karsanbhai to its Board of Directors.
    Difference
    73%
    Check dated 2024-11-23T04:43:37.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    Merck has received a positive EU CHMP opinion for KEYTRUDA® in treating malignant pleural mesothelioma and has entered an exclusive global license for an investigational bispecific antibody, while notable deletions include recent data on various investigational treatments and collaborations.
    Difference
    53%
    Check dated 2024-11-15T23:55:53.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The website has added a comprehensive menu with sections on sustainability, research, products, and investor resources, while removing a specific news release about Merck's KEYTRUDA® treatment results.
    Difference
    49%
    Check dated 2024-11-08T18:28:51.000Z thumbnail image

Stay in the know with updates to Merck & Co. Press Releases

Enter your email address, and we'll notify you when there's something new on the Merck & Co. Press Releases page.